180 related articles for article (PubMed ID: 37547287)
1. Branchpoints as potential targets of exon-skipping therapies for genetic disorders.
Ohara H; Hosokawa M; Awaya T; Hagiwara A; Kurosawa R; Sako Y; Ogawa M; Ogasawara M; Noguchi S; Goto Y; Takahashi R; Nishino I; Hagiwara M
Mol Ther Nucleic Acids; 2023 Sep; 33():404-412. PubMed ID: 37547287
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide induced pseudoexon skipping and restoration of functional protein for Fukuyama muscular dystrophy caused by a deep-intronic variant.
Enkhjargal S; Sugahara K; Khaledian B; Nagasaka M; Inagaki H; Kurahashi H; Koshimizu H; Toda T; Taniguchi-Ikeda M
Hum Mol Genet; 2023 Apr; 32(8):1301-1312. PubMed ID: 36426838
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy.
Taniguchi-Ikeda M; Kobayashi K; Kanagawa M; Yu CC; Mori K; Oda T; Kuga A; Kurahashi H; Akman HO; DiMauro S; Kaji R; Yokota T; Takeda S; Toda T
Nature; 2011 Oct; 478(7367):127-31. PubMed ID: 21979053
[TBL] [Abstract][Full Text] [Related]
4. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
5. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
6. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
7. [Current status and future prospects of research on Fukuyama muscular dystrophy].
Toda T
Nihon Rinsho; 2015 Aug; 73(8):1425-36. PubMed ID: 26281700
[TBL] [Abstract][Full Text] [Related]
8. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
Rodrigues M; Yokota T
Methods Mol Biol; 2018; 1828():31-55. PubMed ID: 30171533
[TBL] [Abstract][Full Text] [Related]
9. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.
van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA
Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788
[TBL] [Abstract][Full Text] [Related]
10. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
Aartsma-Rus A; Houlleberghs H; van Deutekom JC; van Ommen GJ; 't Hoen PA
Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
[TBL] [Abstract][Full Text] [Related]
11. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide-mediated exon skipping of CHRNA1 pre-mRNA as potential therapy for Congenital Myasthenic Syndromes.
Tei S; Ishii HT; Mitsuhashi H; Ishiura S
Biochem Biophys Res Commun; 2015 Jun; 461(3):481-6. PubMed ID: 25888793
[TBL] [Abstract][Full Text] [Related]
13. AON-mediated Exon Skipping Restores Ciliation in Fibroblasts Harboring the Common Leber Congenital Amaurosis CEP290 Mutation.
Gerard X; Perrault I; Hanein S; Silva E; Bigot K; Defoort-Delhemmes S; Rio M; Munnich A; Scherman D; Kaplan J; Kichler A; Rozet JM
Mol Ther Nucleic Acids; 2012 Jun; 1(6):e29. PubMed ID: 23344081
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic potential of antisense-mediated exon skipping.
van Ommen GJ; van Deutekom J; Aartsma-Rus A
Curr Opin Mol Ther; 2008 Apr; 10(2):140-9. PubMed ID: 18386226
[TBL] [Abstract][Full Text] [Related]
15. Deep-intronic variant of fukutin is the most prevalent point mutation of Fukuyama congenital muscular dystrophy in Japan.
Kobayashi K; Kato R; Kondo-Iida E; Taniguchi-Ikeda M; Osawa M; Saito K; Toda T
J Hum Genet; 2017 Nov; 62(11):945-948. PubMed ID: 28680109
[TBL] [Abstract][Full Text] [Related]
16. A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.
Pramono ZA; Wee KB; Wang JL; Chen YJ; Xiong QB; Lai PS; Yee WC
Hum Gene Ther; 2012 Jul; 23(7):781-90. PubMed ID: 22486275
[TBL] [Abstract][Full Text] [Related]
17. Exon-Skipping for a Pathogenic COL6A1 Variant in Ullrich Congenital Muscular Dystrophy.
Aguti S; Guirguis F; Bönnemann C; Muntoni F; Bolduc V; Zhou H
Methods Mol Biol; 2023; 2587():387-407. PubMed ID: 36401040
[TBL] [Abstract][Full Text] [Related]
18. GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells.
van der Wal E; Bergsma AJ; van Gestel TJM; In 't Groen SLM; Zaehres H; Araúzo-Bravo MJ; Schöler HR; van der Ploeg AT; Pijnappel WWMP
Mol Ther Nucleic Acids; 2017 Jun; 7():101-115. PubMed ID: 28624186
[TBL] [Abstract][Full Text] [Related]
19. Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening.
O'Leary DA; Sharif O; Anderson P; Tu B; Welch G; Zhou Y; Caldwell JS; Engels IH; Brinker A
PLoS One; 2009 Dec; 4(12):e8348. PubMed ID: 20020055
[TBL] [Abstract][Full Text] [Related]
20. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.
Aartsma-Rus A; van Ommen GJ
RNA; 2007 Oct; 13(10):1609-24. PubMed ID: 17684229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
